Osteoporosis therapies and their mechanisms of action (Review)
- Authors:
- Beomchang Kim
- Yong Jin Cho
- Wonbong Lim
-
Affiliations: Laboratory of Orthopaedic Research, School of Medicine, Chosun University, Gwangju 61452, Republic of Korea, Department of Orthopaedic Surgery, College of Medicine, Chosun University, Gwangju 61452, Republic of Korea - Published online on: September 28, 2021 https://doi.org/10.3892/etm.2021.10815
- Article Number: 1379
-
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, Van K and Hyun D: Osteoporosis: A review of treatment options. P T. 43:92–104. 2018.PubMed/NCBI | |
|
Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BE, Barrett-Connor E, Black D, Bonjour JP, et al: Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporosis Int. 10:259–264. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Noh JY, Yang Y and Jung H: Molecular mechanisms and emerging therapeutics for osteoporosis. Int J Mol Sci. 21(7623)2020.PubMed/NCBI View Article : Google Scholar | |
|
Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S and Dawson-Hughes B: The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 29:2520–2526. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Langdahl BL: Overview of treatment approaches to osteoporosis. Br J Pharmacol. 178:1891–1906. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A and Tosteson A: Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 22:465–475. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Langdahl BL and Harsløf T: Medical treatment of osteoporotic vertebral fractures. Ther Adv Musculoskelet Dis. 3:17–29. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, et al: American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016. Endocr Pract. 22 (Suppl 4):S1–S42. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Akkawi I and Zmerly H: Osteoporosis: Current concepts. Joints. 6:122–127. 2018.PubMed/NCBI View Article : Google Scholar | |
|
De Martinis M, Sirufo MM and Ginaldi L: Osteoporosis: Current and emerging therapies targeted to immunological checkpoints. Curr Med Chem. 27:6356–6372. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Milat F and Ebeling PR: Osteoporosis treatment: A missed opportunity. Med J Aust. 205:185–190. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S and Lindsay R: National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 25:2359–2381. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Nuti R, Brandi ML, Checchia G, Di Munno O, Dominguez L, Falaschi P, Fiore CE, Iolascon G, Maggi S, Michieli R, et al: Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med. 14:85–102. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Marshall D, Johnell O and Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 312:1254–1259. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Szulc P and Delmas PD: Biochemical markers of bone turnover: Potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int. 19:1683–1704. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Dempster D, Cauley J, Bouxsein M and Cosman F (eds.): Lessons from bone histomorphometry on the mechanisms of action of osteoporosis drugs. In: Marcus and Feldman's Osteoporosis. 5th edition. Academic Press, Cambridge, MA, USA, pp1835-1863, 2020. | |
|
Schuiling KD, Robinia K and Nye R: Osteoporosis update. J Midwifery Womens Health. 56:615–627. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Zmuda JM, Sheu YT and Moffett SP: The search for human osteoporosis genes. J Musculoskelet Neuronal Interact. 6:3–15. 2006.PubMed/NCBI | |
|
Sadler C and Huff M: African-American women: Health beliefs, lifestyle, and osteoporosis. Orthop Nurs. 26:96–101. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F and Rizzoli R: European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 19:399–428. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Kuo TR and Chen CH: Bone biomarker for the clinical assessment of osteoporosis: Recent developments and future perspectives. Biomark Res. 5(18)2017.PubMed/NCBI View Article : Google Scholar | |
|
Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA and Owens DK: Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American college of physicians. Ann Intern Med. 149:404–415. 2008.PubMed/NCBI | |
|
Wada T, Nakashima T, Hiroshi N and Penninger JM: RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 12:17–25. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Li H, Xiao Z, Quarles LD and Li W: Osteoporosis: Mechanism, molecular target and current status on drug development. Curr Med Chem. 28:1489–1507. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:3597–3602. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS III, Frankel WN, et al: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 272:25190–25194. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Park JH, Lee NK and Lee SY: Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol Cells. 40:706–713. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Xu F and Teitelbaum SL: Osteoclasts: New insights. Bone Res. 1:11–26. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Yamashita T, Takahashi N and Udagawa N: New roles of osteoblasts involved in osteoclast differentiation. World J Orthop. 3:175–181. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Rucci N: Molecular biology of bone remodelling. Clin Cases Miner Bone Metab. 5:49–56. 2008.PubMed/NCBI | |
|
Teitelbaum SL: Bone resorption by osteoclasts. Science. 289:1504–1508. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Hienz SA, Paliwal S and Ivanovski S: Mechanisms of bone resorption in periodontitis. J Immunol Res. 2015(615486)2015.PubMed/NCBI View Article : Google Scholar | |
|
Das S and Crockett JC: Osteoporosis-a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 7:435–448. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Henriksen K, Bollerslev J, Everts V and Karsdal MA: Osteoclast activity and subtypes as a function of physiology and pathology-implications for future treatments of osteoporosis. Endocr Rev. 32:31–63. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Arnett T: Regulation of bone cell function by acid-base balance. Proc Nutr Soc. 62:511–520. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Blair HC, Zaidi M, Huang CL and Sun L: The developmental basis of skeletal cell differentiation and the molecular basis of major skeletal defects. Biol Rev Camb Philos Soc. 83:401–415. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 284:143–147. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Nakashima K and de Crombrugghe B: Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet. 19:458–466. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Brighton CT and Hunt RM: Histochemical localization of calcium in the fracture callus with potassium pyroantimonate. Possible role of chondrocyte mitochondrial calcium in callus calcification. J Bone Joint Surg Am. 68:703–715. 1986.PubMed/NCBI | |
|
de Crombrugghe B, Lefebvre V and Nakashima K: Regulatory mechanisms in the pathways of cartilage and bone formation. Curr Opin Cell Biol. 13:721–727. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Brighton CT and Hunt RM: Early histological and ultrastructural changes in medullary fracture callus. J Bone Joint Surg Am. 73:832–847. 1991.PubMed/NCBI | |
|
Soltanoff CS, Yang S, Chen W and Li YP: Signaling networks that control the lineage commitment and differentiation of bone cells. Crit Rev Eukaryot Gene Expr 19, 2009. | |
|
Chau JF, Leong WF and Li B: Signaling pathways governing osteoblast proliferation, differentiation and function. Histol Histopathol. 24:1593–1606. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Meyer MB, Benkusky NA and Pike JW: The RUNX2 cistrome in osteoblasts: Characterization, down-regulation following differentiation, and relationship to gene expression. J Biol Chem. 289:16016–16031. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Lin GL and Hankenson KD: Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. J Cell Biochem. 112:3491–3501. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Burch J, Rice S, Yang H, Neilson A, Stirk L, Francis R, Holloway P, Selby P and Craig D: Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: The secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technol Assess. 18:1–180. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Mori G, D'Amelio P, Faccio R and Brunetti G: The interplay between the bone and the immune system. Clin Dev Immunol. 2013(720504)2013.PubMed/NCBI View Article : Google Scholar | |
|
Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J and Dansey R: Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 11:401–419. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Noble BS: The osteocyte lineage. Arch Biochem Biophys. 473:106–111. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Klein-Nulend J, Nijweide PJ and Burger EH: Osteocyte and bone structure. Curr Osteoporos Rep. 1:5–10. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Rochefort GY: The osteocyte as a therapeutic target in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 6:79–91. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Bonewald LF: The amazing osteocyte. J Bone Miner Res. 26:229–238. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, et al: Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 17:1231–1234. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Goldring SR: The osteocyte: Key player in regulating bone turnover. RMD Open. 1 (Suppl 1)(e000049)2015.PubMed/NCBI View Article : Google Scholar | |
|
Moriishi T, Fukuyama R, Ito M, Miyazaki T, Maeno T, Kawai Y, Komori H and Komori T: Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading. PLoS One. 7(e40143)2012.PubMed/NCBI View Article : Google Scholar | |
|
Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF and Kneissel M: Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 30:3071–3085. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Bellido T: Osteocyte apoptosis induces bone resorption and impairs the skeletal response to weightlessness. IBMS BoneKEy. 4(252)2007. | |
|
Chamoux E, Houde N, L'eriger K and Roux S: Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol. 216:536–542. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Yen ML, Hsu PN, Liao HJ, Lee BH and Tsai HF: TRAF-6 dependent signaling pathway is essential for TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation. PLoS One. 7(e38048)2012.PubMed/NCBI View Article : Google Scholar | |
|
Bikle DD: Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 21:319–329. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Norman AW: From vitamin D to hormone D: Fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr. 88:491S–499S. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Valero Zanuy M and Hawkins Carranza F: Metabolism, endogenous and exogenous sources of vitamin D. Rev Esp Enferm Metab Oseas. 16:63–70. 2007. | |
|
Silva MC and Furlanetto TW: Intestinal absorption of vitamin D: A systematic review. Nutr Rev. 76:60–76. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Compston JE, Merrett AL, Hammett FG and Magill P: Comparison of the appearance of radiolabelled vitamin D3 and 25-hydroxy-vitamin D3 in the chylomicron fraction of plasma after oral administration in man. Clin Sci (Lond). 60:241–243. 1981.PubMed/NCBI View Article : Google Scholar | |
|
Gil A, Plaza-Diaz J and Mesa MD: Vitamin D: Classic and novel actions. Ann Nutr Metab. 72:87–95. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Naveh-Many T, Marx R, Keshet E, Pike JW and Silver J: Regulation of 1, 25-dihydroxyvitamin D3 receptor gene expression by 1, 25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest. 86:1968–1975. 1990.PubMed/NCBI View Article : Google Scholar | |
|
Glendenning P, Ratajczak T, Dick IM and Prince RL: Calcitriol upregulates expression and activity of the 1b isoform of the plasma membrane calcium pump in immortalized distal kidney tubular cells. Arch Biochem Biophys. 380:126–132. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Kuchuk NO, van Schoor NM, Pluijm SM, Chines A and Lips P: Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: Global perspective. J Bone Miner Res. 24:693–701. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Harada S, Mizoguchi T, Kobayashi Y, Nakamichi Y, Takeda S, Sakai S, Takahashi F, Saito H, Yasuda H, Udagawa N, et al: Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res. 27:461–473. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Takeda S, Yoshizawa T, Nagai Y, Yamato H, Fukumoto S, Sekine K, Kato S, Matsumoto T and Fujita T: Stimulation of osteoclast formation by 1, 25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinology. 140:1005–1008. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Christakos S, Dhawan P, Verstuyf A, Verlinden L and Carmeliet G: Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev. 96:365–408. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Kim S, Yamazaki M, Zella LA, Shevde NK and Pike JW: Activation of receptor activator of NF-kappaB ligand gene expression by 1, 25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol. 26:6469–6486. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Ukon Y, Makino T, Kodama J, Tsukazaki H, Tateiwa D, Yoshikawa H and Kaito T: Molecular-based treatment strategies for osteoporosis: A literature review. Int J Mol Sci. 20(2557)2019.PubMed/NCBI View Article : Google Scholar | |
|
Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, et al: American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 16 (Suppl 3):S1–S37. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kim SY, Zhang M and Bockman R: Bone mineral density response from teriparatide in patients with osteoporosis. HSS J. 13:171–177. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Estell EG and Rosen CJ: Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis. Nat Rev Endocrinol. 17:31–46. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Pavone V, Testa G, Giardina SMC, Vescio A, Restivo DA and Sessa G: Pharmacological therapy of osteoporosis: A systematic current review of literature. Front Pharmacol. 8(803)2017.PubMed/NCBI View Article : Google Scholar | |
|
North American Menopause Societ. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American menopause society. Menopause. 13:340–367; quiz 368-9. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Drake MT, Clarke BL and Khosla S: Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 83:1032–1045. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M, Patella V, Zambonin Zallone A and Grano M: Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int. 63:230–235. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E and Rodan GA: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 88:2095–2105. 1991.PubMed/NCBI View Article : Google Scholar | |
|
Papapoulos SE: Bisphosphonates: How do they work? Best Pract Res Clin Endocrinol Metab. 22:831–847. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Russell RG: Bisphosphonates: The first 40 years. Bone. 49:2–19. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Barnsley J, Buckland G, Chan PE, Ong A, Ramos AS, Baxter M, Laskou F, Dennison EM, Cooper C and Patel HP: Pathophysiology and treatment of osteoporosis: Challenges for clinical practice in older people. Aging Clin Exp Res. 33:759–773. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Garg MK and Kharb S: Dual energy X-ray absorptiometry: Pitfalls in measurement and interpretation of bone mineral density. Indian J Endocrinol Metab. 17:203–210. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Rogers MJ: From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int. 75:451–461. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Russell RG: Bisphosphonates: Mode of action and pharmacology. Pediatrics. 119 (Suppl 2):S150–S162. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Dunford JE: Molecular targets of the nitrogen containing bisphosphonates: The molecular pharmacology of prenyl synthase inhibition. Curr Pharm Des. 16:2961–2969. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kanis JA, Cooper C, Rizzoli R and Reginster JY: Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 30:3–44. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Simon JA: Are all bisphosphonates the same? Potential reasons for clinical differences: A perspective. J Womens Health (Larchmt). 19:719–727. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Qaseem A, Forciea MA, McLean RM and Denberg TD: Clinical Guidelines Committee of the American College of Physicians. Barry MJ, Cooke M, Fitterman N, Harris RP, Humphrey LL, et al: Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the American College of Physicians. Ann Intern Med. 166:818–839. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Nelson HD, Haney EM, Dana T, Bougatsos C and Chou R: Screening for osteoporosis: An update for the US preventive services task force. Ann Intern Med. 153:99–111. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ and Laupacis A: Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 305:783–789. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, Giusti A, Malavolta N, Minisola S, Osella G, et al: Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo. 68:1–39. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Pazianas M and Abrahamsen B: Osteoporosis treatment: Bisphosphonates reign to continue for a few more years, at least? Ann N Y Acad Sci. 1376:5–13. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Lorentzon M: Treating osteoporosis to prevent fractures: Current concepts and future developments. J Intern Med. 285:381–394. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R and Zillikens MC: Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 105:11–17. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK and van der Heijde D: Effect of denosumab on Japanese patients with rheumatoid arthritis: A dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis. 75:983–990. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, et al: 10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5:513–523. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Tabatabaei-Malazy O, Salari P, Khashayar P and Larijani B: New horizons in treatment of osteoporosis. DARU. 25(2)2017.PubMed/NCBI View Article : Google Scholar | |
|
Bonani M, Frey D, de Rougemont O, Mueller NJ, Mueller TF, Graf N and Wüthrich RP: Infections in de novo kidney transplant recipients treated with the RANKL inhibitor denosumab. Transplantation. 101:2139–2145. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Törring O, Valter I, Wang AT and Brown JP: Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 33:190–198. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Krum SA and Brown M: Unraveling estrogen action in osteoporosis. Cell Cycle. 7:1348–1352. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R and Reginster JY: Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 24:23–57. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Lobo RA, Pickar JH, Stevenson JC, Mack WJ and Hodis HN: Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis. 254:282–290. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Cartwright B, Robinson J, Seed PT, Fogelman I and Rymer J: Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: A randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab. 101:3497–3505. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:321–333. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Maximov PY, Lee TM and Jordan VC: The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 8:135–155. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Siddiqui JA and Partridge NC: Physiological bone remodeling: Systemic regulation and growth factor involvement. Physiology (Bethesda). 31:233–245. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Gillespie MT, et al: Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone. 46:1486–1497. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Keller J, Catala-Lehnen P, Huebner AK, Jeschke A, Heckt T, Lueth A, Krause M, Koehne T, Albers J, Schulze J, et al: Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. Nat Commun. 5(5215)2014.PubMed/NCBI View Article : Google Scholar | |
|
Bandeira L, Lewiecki EM and Bilezikian JP: Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. Expert Opin Drug Metab Toxicol. 12:681–689. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Drake MT, Clarke BL, Oursler MJ and Khosla S: Cathepsin K inhibitors for osteoporosis: Biology, potential clinical utility, and lessons learned. Endocr Rev. 38:325–350. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Dai R, Wu Z, Chu HY, Lu J, Lyu A, Liu J and Zhang G: Cathepsin K: The action in and beyond bone. Front Cell Dev Biol. 8(433)2020.PubMed/NCBI View Article : Google Scholar | |
|
Takito J, Inoue S and Nakamura M: The sealing zone in osteoclasts: A self-organized structure on the bone. Int J Mol Sci. 19(984)2018.PubMed/NCBI View Article : Google Scholar | |
|
Fonović M and Turk B: Cysteine cathepsins and extracellular matrix degradation. Biochim Biophys Acta. 1840:2560–2570. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Mullard A: Merck & Co. drops osteoporosis drug odanacatib. Nat Rev Drug Discov. 15(669)2016.PubMed/NCBI View Article : Google Scholar | |
|
Brömme D and Lecaille F: Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs. 18:585–600. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Eastell R, Nagase S, Ohyama M, Small M, Sawyer J, Boonen S, Spector T, Kuwayama T and Deacon S: Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study. J Bone Miner Res. 26:1303–1312. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Stoch SA, Zajic S, Stone JA, Miller DL, van Bortel L, Lasseter KC, Pramanik B, Cilissen C, Liu Q, Liu L, et al: Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics-results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol. 75:1240–1254. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Khan B, Ahmed Z and Ahmad W: A novel missense mutation in cathepsin K (CTSK) gene in a consanguineous Pakistani family with pycnodysostosis. J Investig Med. 58:720–724. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Iñiguez-Ariza NM and Clarke BL: Bone biology, signaling pathways, and therapeutic targets for osteoporosis. Maturitas. 82:245–255. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Chapurlat RD: Odanacatib: A review of its potential in the management of osteoporosis in postmenopausal women. Ther Adv Musculoskelet Dis. 7:103–109. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Marie PJ: The calcium-sensing receptor in bone cells: A potential therapeutic target in osteoporosis. Bone. 46:571–576. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Spector TD, Calomme MR, Anderson SH, Clement G, Bevan L, Demeester N, Swaminathan R, Jugdaohsingh R, Berghe DA and Powell JJ: Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: A randomized, placebo-controlled trial. BMC Musculoskelet Disord. 9(85)2008.PubMed/NCBI View Article : Google Scholar | |
|
Hamdy NA: Strontium ranelate improves bone microarchitecture in osteoporosis. Rheumatology (Oxford). 48 (Suppl 4):iv9–iv13. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Pilmane M, Salma-Ancane K, Loca D, Locs J and Berzina-Cimdina L: Strontium and strontium ranelate: Historical review of some of their functions. Mater Sci Eng C Mater Biol Appl. 78:1222–1230. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Delany AM, Amling M, Priemel M, Howe C, Baron R and Canalis E: Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest. 105:915–923. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Kanis JA, Johansson H, Oden A and McCloskey EV: A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. Osteoporos Int. 22:2347–2355. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Bolland MJ and Grey A: A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. BMJ Open. 4(e005787)2014.PubMed/NCBI View Article : Google Scholar | |
|
Mi B, Xiong W, Xu N, Guan H, Fang Z, Liao H, Zhang Y, Gao B, Xiao X, Fu J and Li F: Strontium-loaded titania nanotube arrays repress osteoclast differentiation through multiple signalling pathways: In vitro and in vivo studies. Sci Rep. 7(2328)2017.PubMed/NCBI View Article : Google Scholar | |
|
Gupta S, Termini JM, Kanagavelu S and Stone GW: Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics. Immunol Res. 57:303–310. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Liu C, Walter TS, Huang P, Zhang S, Zhu X, Wu Y, Wedderburn LR, Tang P, Owens RJ, Stuart DI, et al: Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol. 184:6910–6919. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Ko YJ, Sohn HM, Jang Y, Park M, Kim B, Kim B, Park JI, Hyun H, Jeong B, Hong C and Lim W: A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor. Clin Transl Med. 11(e368)2021.PubMed/NCBI View Article : Google Scholar | |
|
Jang Y, Sohn HM, Ko YJ, Hyun H and Lim W: Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL. Int J Mol Sci. 22(434)2021.PubMed/NCBI View Article : Google Scholar | |
|
Liu C, Zhao Y, He W, Wang W, Chen Y, Zhang S, Ma Y, Gohda J, Ishida T, Walter TS, et al: A RANKL mutant used as an inter-species vaccine for efficient immunotherapy of osteoporosis. Sci Rep. 5(14150)2015.PubMed/NCBI View Article : Google Scholar | |
|
Wu T, Li F, Sha X, Li F, Zhang B, Ma W, Liu M, Yang W, Li H and Tao H: A novel recombinant RANKL vaccine prepared by incorporation of an unnatural amino acid into RANKL and its preventive effect in a murine model of collagen-induced arthritis. Int Immunopharmacol. 64:326–332. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ling L, Hu HL, Liu KY, Ram YI, Gao JL and Cao YM: Long noncoding RNA MIRG induces osteoclastogenesis and bone resorption in osteoporosis through negative regulation of miR-1897. Eur Rev Med Pharmacol Sci. 23:10195–10203. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Wu QY, Li X, Miao ZN, Ye JX, Wang B, Zhang F, Xu RS, Jiang DL, Zhao MD and Yuan FL: Long Non-coding RNAs: A new regulatory code for osteoporosis. Front Endocrinol (Lausanne). 9(587)2018.PubMed/NCBI View Article : Google Scholar | |
|
Zhu J, Yu W, Wang Y, Xia K, Huang Y, Xu A, Chen Q, Liu B, Tao H, Li F and Liang C: lncRNAs: function and mechanism in cartilage development, degeneration, and regeneration. Stem Cell Res Ther. 10(344)2019.PubMed/NCBI View Article : Google Scholar | |
|
Wijnen WJ, Pinto YM and Creemers EE: The therapeutic potential of miRNAs in cardiac fibrosis: Where do we stand? J Cardiovasc Transl Res. 6:899–908. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Mandourah AY, Ranganath L, Barraclough R, Vinjamuri S, Hof RV, Hamill S, Czanner G, Dera AA, Wang D and Barraclough DL: Circulating microRNAs as potential diagnostic biomarkers for osteoporosis. Sci Rep. 8(8421)2018.PubMed/NCBI View Article : Google Scholar | |
|
Rachner TD, Hofbauer LC, Göbel A and Tsourdi E: Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin. J Mol Endocrinol. 62:R145–R154. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Borba VZ and Mañas NC: The use of PTH in the treatment of osteoporosis. Arq Bras Endocrinol Metabol. 54:213–219. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Silva BC and Bilezikian JP: Parathyroid hormone: Anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol. 22:41–50. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Gardella T: Interactions of PTH with Receptors and Signaling. The Parathyroids: Basic and Clinical Concepts. Third ed. Elsevier Inc: 65-80, 2015. | |
|
Datta NS and Abou-Samra AB: PTH and PTHrP signaling in osteoblasts. Cell Signal. 21(8):1245–1254. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Migliaccio S, Brama M and Malavolta N: Management of glucocorticoids-induced osteoporosis: Role of teriparatide. Ther Clin Risk Manag. 5:305–310. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Recker RR, Marin F, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Farrerons J, Sanz B, et al: Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res. 24:1358–1368. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Rubin MR and Bilezikian JP: New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am. 32:285–307. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, Belleli R, Wright TM and John MR: Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 45:1053–1058. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Cosman F: Abaloparatide: A new anabolic therapy on the horizon. Bonekey Rep. 4(661)2015.PubMed/NCBI View Article : Google Scholar | |
|
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, et al: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344:1434–1441. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Fukumoto S and Matsumoto T: Recent advances in the management of osteoporosis. F1000Research. 6(625)2017.PubMed/NCBI View Article : Google Scholar | |
|
Cheloha RW, Gellman SH, Vilardaga JP and Gardella TJ: PTH receptor-1 signalling-mechanistic insights and therapeutic prospects. Nat Rev Endocrinol. 11:712–724. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Hattersley G, Dean T, Corbin BA, Bahar H and Gardella TJ: Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 157:141–149. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Boyce EG, Mai Y and Pham C: Abaloparatide: Review of a next-generation parathyroid hormone agonist. Ann Pharmacother. 52:462–472. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Gensure RC, Gardella TJ and Jüppner H: Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun. 328:666–678. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Wysolmerski JJ: Parathyroid hormone-related protein: An update. J Clin Endocrinol Metab. 97:2947–2956. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Iolascon G, Moretti A, Toro G, Gimigliano F, Liguori S and Paoletta M: Pharmacological therapy of osteoporosis: What's new? Clin Interv Aging. 15:485–491. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Pietrzyk B, Smertka M and Chudek J: Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Adv Clin Exp Med. 26:1283–1291. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Lerner UH and Ohlsson C: The WNT system: background and its role in bone. J Intern Med. 277:630–649. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE and Wu D: Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 280:19883–19887. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, et al: Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 375:1532–1543. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Canalis E: Management of endocrine disease: Novel anabolic treatments for osteoporosis. Eur J Endocrinol. 178:R33–R44. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP and Rosen CJ: PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 349:1207–1215. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Lou S, Lv H, Yin P, Li Z, Tang P and Wang Y: Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 30:59–70. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H and Neer RM: Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): A randomized controlled trial. J Clin Endocrinol Metab. 99:1694–1700. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Kitaguchi K, Kashii M, Ebina K, Kaito T, Okada R, Makino T, Noguchi T, Ishimoto T, Nakano T and Yoshikawa H: Effects of single or combination therapy of teriparatide and anti-RANKL monoclonal antibody on bone defect regeneration in mice. Bone. 106:1–10. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD and Grauer A: Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 377:1417–1427. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, et al: Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial. Lancet. 390:1585–1594. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, et al: ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 103:2949–2957. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM and Burnett-Bowie SA: Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet. 386:1147–1155. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Bell NH and Johnson RH: Bisphosphonates in the treatment of osteoporosis. Endocrine. 6:203–206. 1997.PubMed/NCBI View Article : Google Scholar |
